Brandy D. Hyndman

Brandy D. Hyndman

Auto-generated profile, based on publicly available information

Brandy D. Hyndman

Division of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen’s University

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
BHBrandy D. Hyndman
Brandy D. Hyndman
MCMathieu Crupi
Mathieu Crupi
SPSusan Peng
Susan Peng
LBLeslie N. Bone
Leslie N. Bone
ARAisha N. Rekab
Aisha N. Rekab
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan
The RET receptor tyrosine kinase is implicated in normal development and cancer. RET is expressed as two isoforms, RET9 and RET51, with unique C-terminal tail sequences that recruit distinct protein complexes to mediate signals. Upon activation, RET isoforms are internalized with distinct kinetics, suggesting differences in regulation. Here, we demonstrate that RET9 and RET51 differ in their abilities to recruit E3 ubiquitin ligases to their unique C-termini. RET51, but not RET9, interacts with, and is ubiquitylated by CBL, which is recruited through interactions with the GRB2 adaptor protein. RET51 internalization was not affected by CBL knockout but was delayed in GRB2-depleted cells. In contrast, RET9 ubiquitylation requires phosphorylation-dependent changes in accessibility of key RET9 C-terminal binding motifs that facilitate interactions with multiple adaptor proteins, including GRB10 and SHANK2, to recruit the NEDD4 ubiquitin ligase. We showed that NEDD4-mediated ubiquitylation is required for RET9 localization to clathrin-coated pits and subsequent internalization. Our data establish differences in the mechanisms of RET9 and RET51 ubiquitylation and internalization that may influence the strength and duration of RET isoform signals and cellular outputs. This article has an associated First Person interview with the first authors of the paper.

23 October 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
MCMathieu J. F. Crupi
Mathieu J. F. Crupi
SMSarah M. Maritan
Sarah M. Maritan
EREduardo Reyes-Alvarez
Eduardo Reyes-Alvarez
ELEric Y. Lian
Eric Y. Lian
BHBrandy D. Hyndman
Brandy D. Hyndman
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan

26 July 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
BHBrandy D. Hyndman
Brandy D. Hyndman
TGTaranjit S. Gujral
Taranjit S. Gujral
JKJonathan R. Krieger
Jonathan R. Krieger
JCJessica G. Cockburn
Jessica G. Cockburn
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan
The REarranged during Transfection (RET) gene encodes a receptor tyrosine kinase required for maturation of the enteric nervous system. RET sequence variants occur in the congenital abnormality Hirschsprung disease (HSCR), characterized by absence of ganglia in the intestinal tract. Although HSCR-RET variants are predicted to inactivate RET, the molecular mechanisms of these events are not well characterized. Using structure-based models of RET, we predicted the molecular consequences of 23 HSCR-associated missense variants and how they lead to receptor dysfunction. We validated our predictions in biochemical and cell-based assays to explore mutational effects on RET protein functions. We found a minority of HSCR-RET variants abrogated RET kinase function, while the remaining mutants were phosphorylated and transduced intracellular signals. HSCR-RET sequence variants also impacted on maturation, stability, and degradation of RET proteins. We showed that each variant conferred a unique combination of effects that together impaired RET protein activity. However, all tested variants impaired RET-mediated cellular functions, including cell transformation and migration. Our data indicate that the molecular mechanisms of impaired RET function in HSCR are highly variable. Although a subset of variants cause loss of RET kinase activity and downstream signaling, enzymatic inactivation is not the sole mechanism at play in HSCR.

1 September 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RBRichard Bayly
Richard Bayly
TMTakayuki Murase
Takayuki Murase
BHBrandy D. Hyndman
Brandy D. Hyndman
RSRachel Savage
Rachel Savage
SNSalima Nurmohamed
Salima Nurmohamed
DLDavid P. LeBrun
David P. LeBrun
In roughly 5% of cases of acute lymphoblastic leukemia, a chromosomal translocation leads to expression of the oncogenic protein E2A-PBX1. The N-terminal portion of E2A-PBX1, encoded by the E2A gene, is identical in sequence to the corresponding portion of the E proteins E12/E47 and includes transcriptional activation domains. The C terminus consists of most of the HOX interacting transcription factor PBX1, including its DNA-binding homeodomain. Structure-function correlative experiments have suggested that oncogenesis by E2A-PBX1 requires an activation domain, called AD1, at the extreme N terminus. We recently demonstrated that a potentially helical portion of AD1 interacts directly with the transcriptional coactivator protein cyclic AMP response element-binding protein (CBP) and that this interaction is essential in the immortalization of primary bone marrow cells in tissue culture. Here we show that a conserved LXXLL motif within AD1 is required in the interaction between E2A-PBX1 and the KIX domain of CBP. We show by circular dichroism spectroscopy that the LXXLL-containing portion of AD1 undergoes a helical transition upon interacting with the KIX domain and that amino acid substitutions that prevent helix formation prevent both the KIX interaction and cell immortalization by E2A-PBX1. Perhaps most strikingly, substitution of a single, conserved leucine residue (L20) within the LXXLL motif impairs leukemia induction in mice after transplantation with E2A-PBX1-expressing bone marrow. The KIX domain of CBP mediates well-characterized interactions with several transcription factors of relevance to leukemia induction. Circumstantial evidence suggests that the side chain of L20 might interact with a deep hydrophobic pocket in the KIX domain. Therefore, our results serve to identify a potential new drug target.

3 September 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
ELEric Y. Lian
Eric Y. Lian
BHBrandy D. Hyndman
Brandy D. Hyndman
SMSerisha Moodley
Serisha Moodley
SMSarah M. Maritan
Sarah M. Maritan
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan

1 April 2020 in Lung Cancer
Verified
Journal Article
Closed access
SMSerisha Moodley
Serisha Moodley
ELEric Y. Lian
Eric Y. Lian
MCMathieu J.F. Crupi
Mathieu J.F. Crupi
BHBrandy D. Hyndman
Brandy D. Hyndman
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan